Advertisement
Advertisement

HRTX

HRTX logo

Heron Therapeutics, Inc.

0.95
USD
Sponsored
-0.02
-1.92%
Mar 09, 14:56 UTC -4
Open

HRTX Earnings Reports

Positive Surprise Ratio

HRTX beat 21 of 40 last estimates.

53%

Next Report

Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$40.92M
/
$0.00
Implied change from Q4 25 (Revenue/ EPS)
+0.82%
/
-100.00%
Implied change from Q1 25 (Revenue/ EPS)
+5.18%
/
-100.00%

Heron Therapeutics, Inc. earnings per share and revenue

On Feb 26, 2026, HRTX reported earnings of -0.02 USD per share (EPS) for Q4 25, beating the estimate of -0.02 USD, resulting in a 1.96% surprise. Revenue reached 40.59 million, compared to an expected 40.32 million, with a 0.65% difference. The market reacted with a +7.19% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of 0.00 USD, with revenue projected to reach 40.92 million USD, implying an decrease of -100.00% EPS, and increase of 0.82% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Harrow, Inc. Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
$0.37
Actual
$0.26
Surprise
-30.87%
logo
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Mar 03, 2026 For Q4 25
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.50%
logo
Bioventus Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.21
Actual
$0.24
Surprise
+9.69%
logo
Altimmune, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.24
Actual
-$0.27
Surprise
-10.16%
logo
Aquestive Therapeutics, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.26
Surprise
-92.31%
logo
OmniAb, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.11
Surprise
-21.82%
logo
Profound Medical Corp. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.27
Surprise
-0.26%
logo
MediWound Ltd.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.56
Surprise
+13.08%
logo
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$1.60
Actual
-$1.25
Surprise
+22.24%
logo
Cumberland Pharmaceuticals Inc
Report Date
Mar 03, 2026 For Q4 25
Estimate
-
Actual
-$0.01
Surprise
-
FAQ
For Q4 2025, Heron Therapeutics, Inc. reported EPS of -$0.02, beating estimates by 1.96%, and revenue of $40.59M, 0.65% above expectations.
The stock price moved up 7.19%, changed from $1.39 before the earnings release to $1.49 the day after.
The next earning report is scheduled for May 04, 2026.
Based on -- analysts, Heron Therapeutics, Inc. is expected to report EPS of -- and revenue of $40.92M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement